• 48°

Guest Opinion: Why are people complaining about innovative COVID treatments?

By Peter J. Pits

Gilead Sciences just announced it will charge $3,120 for a full course of Remdesivir, the first new FDA-approved treatment for COVID-19. Some knee-jerk members of Congress like Lloyd Doggett (D-Tex.) immediately condemned that price tag as “outrageous.” The Institute for Clinical and Economic Review, a left-leaning nonprofit that releases its own recommendations of “fair” drug prices, claimed that Gilead could afford to price Remdesivir as low as $10 per course of treatment – the cost of the raw ingredients used to make the drug.

Ignorance is not bliss. These critics couldn’t be more misinformed. Gilead priced Remdesivir lower than the drug’s actual value. And while it’s no silver bullet, it’s currently our best hope of saving hospitalized patients and reducing strain on our hospitals – a particularly important goal in light of the surging case counts in many states.

Remdesivir isn’t a vaccine. It prevents the virus from replicating within the body. In a Phase III clinical trial, patients who received Remdesivir recovered 31% faster from COVID-19 than those who did not, a decrease from 15 days to 11 days.

Of course, developing Remdesivir wasn’t easy or inexpensive. By the end of 2020, Gilead will have spent $1 billion doing so. The firm began development in 2009, originally intending to use the antiviral to treat Ebola. That enormous investment of time and money helps explain Gilead’s price. Just like any business, it needs to recoup its investment costs.

Here’s the real headline: Gilead didn’t even try to maximize its profits. According to Gilead CEO Daniel O’Day, drug companies normally price their treatments based on how much the medicines save health-care and insurance providers. Reducing each patient’s hospital stay by four days, on average, would save about $12,000. In other words, Gilead could have charged almost $9,000 more. They didn’t.

Gilead didn’t merely leave profits on the table. The firm also provided Remdesivir’s genetic marker to 127 developing countries, allowing foreign manufacturers to create generic versions for local use. In addition to directly healing patients, Remdesivir saves lives by shortening average recovery times, freeing up hospital beds and enabling doctors to treat other patients who might otherwise go without adequate care.

You don’t have to be a math whiz to see the value there. Considering that Arizona, Florida, California and other states continue to report record numbers of COVID-19 cases, keeping hospital beds open must be a top priority. Criticizing the price of the only effective treatment we currently have is misguided at best and ideologically deranged at worst.

Though by no means a cure, Remdesivir helps patients recover faster and eases pressure on hospitals. What’s really “outrageous” are the bad-faith arguments from lawmakers who never pass up an opportunity to attack drug companies. Let’s hope ordinary citizens can see who’s really working to protect patients, and who’s merely demagoguing.

Peter Pitts, a former FDA associate commissioner, is president of the Center for Medicine in the Public Interest, which is partially funded by pharmaceutical companies.

FOR MORE COLUMNS AND LETTERS TO THE EDITOR, CHECK OUT OUR OPINION SECTION HERE.

Hyde

Food box distribution Thursday for Hyde County

Lifestyles

WinterLights: Holiday displays bring a decade of cheer

Lifestyles

Free health screenings for those in fishing industry

News

State and local COVID-19 case count update; additional COVID-related death reported in Dare

News

2017 ban on local LGBT ordinances ends in North Carolina

News

Additional COVID-19 death reported in Bertie County

Crime

Deputies: Woman shot man, robbed store in North Carolina crime spree

News

Criminal record, sentence changes among new North Carolina laws

Currituck

Currituck 4-H program helps with weekend meals for students in need

News

First female Senate majority leader elected in North Carolina

Lifestyles

No turning back: How living in a van has led John Demer to extraordinary places and people

Lifestyles

Giving back to the sounds by recycling for reefs

Hyde

Christmas concerts with David Roach set in Columbia, Swan Quarter and Plymouth

Crime

Man gets prison time for false bomb threats made to schools

News

Gaddy Endowment Fund donates $100k to Manteo Middle School

News

Man dies after 50-foot fall in North Carolina state park

News

15-year-old boy dead, brother injured in North Carolina campground fire

Hyde

Portion of NC 12 on Ocracoke Island closed, standing water on NC 12 on Hatteras Island reported

Lifestyles

Checks presented to non-profits at Dare BOC meet

Lifestyles

Blood drive set for Tuesday and Wednesday in Kitty Hawk

News

Weekly North Carolina gas price update

Crime

Currituck man charged in Camden County and Elizabeth City armed robberies

News

Man shot by police after traffic stop in North Carolina

Crime

Police: Man charged with attempted murder in North Carolina machete attack